Meticulous Research®, a prominent global market research and consulting firm, has published a new research report titled “Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized), Type (Live Attenuated, mRNA, Inactivated), Virus (Adenovirus, Retrovirus, Plasmid DNA, AAV), Approach, Indication, Application, Packaging—Global Forecast to 2031.” The report indicates that the viral vaccines market is poised to reach an estimated $47.01 billion by 2031, growing at a compound annual growth rate (CAGR) of 1.9% from 2024 to 2031.

Download Free Sample Report Here : https://www.meticulousresearch.com/download-sample-report/cp_id=5920?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=30-09-2024

The anticipated growth in the viral vaccines market can be attributed to several driving factors, including a robust pipeline of vaccine products, increased government initiatives aimed at immunization, advancements in vaccine administration technologies, and the rising utilization of inactivated vaccines for surgical treatments. Additionally, the ongoing capacity expansion of biopharmaceutical products, growing interest in therapeutic vaccines, and the development of energy-efficient ultra-low temperature freezers are expected to provide lucrative opportunities for market participants.

Market Segmentation and Key Trends
The viral vaccines market is meticulously segmented into various categories, including form (liquid and lyophilized), vaccine type (live-attenuated, inactivated, mRNA, viral vector, subunit & conjugate, toxoid, and combination vaccines), virus type (adenovirus, retrovirus, plasmid DNA, adeno-associated virus (AAV), lentivirus, and other viruses), route of administration (intramuscular, subcutaneous, oral, and other routes), approach (preventive and therapeutic vaccines), indication (infectious diseases, cancer, genetic disorders, and other indications), application (antisense therapy, gene therapy, cell therapy, and vaccinology), packaging (vials, prefilled syringes), and geography.

This comprehensive analysis also encompasses an evaluation of industry competitors, along with a regional and country-level market analysis to provide a holistic view of the current landscape and future growth potential.

Form: Liquid Vaccines to Dominate the Market
The liquid vaccines segment is projected to capture the largest share of the market by 2024. This preference is driven by several factors, including ease of administration, which eliminates the need for reconstitution, and reduced risk of handling errors. Liquid vaccines simplify logistics compared to their lyophilized counterparts, minimizing equipment and training requirements, and decreasing contamination risks. The growing prevalence of infectious diseases and reduced wastage of vaccine accessories further bolster the liquid vaccines market.

Type: Subunit & Conjugate Vaccines to Lead
In terms of vaccine type, subunit and conjugate vaccines are expected to hold the largest market share in 2024. The popularity of this segment can be attributed to the absence of live components, precise targeting of pathogens, and a low risk of immunogenicity. This results in the elicitation of a protective immune response and long-term immunity, making subunit and conjugate vaccines a preferred choice in the market.

Virus Type: Adenovirus Segment to Hold Major Share
The adenovirus segment is forecasted to dominate the viral vaccines market by 2024, owing to its efficiency in gene delivery, strong immune response, and high scalability. Collaborations among institutions, organizations, and companies are expected to increase the number of immunizations against various infectious diseases. For instance, a recent collaboration involving ReiThera Srl (Italy) and the International AIDS Vaccine Initiative (IAVI) aims to develop an innovative HIV vaccine candidate utilizing ReiThera’s GRAd vector technology, showcasing the ongoing commitment to advancing viral vaccine research.

Approach: Preventive Vaccines to Lead Market Share
The preventive vaccines segment is projected to account for the larger share of the market in 2024. This trend reflects the growing focus on preventing infections caused by viruses and bacteria. Factors contributing to this segment's growth include rising chronic and infectious disease prevalence, increased public awareness of immunization, expanding vaccination programs, and the critical need to induce herd immunity and prevent disease outbreaks.

Indication: Infectious Diseases to Dominate
Among all indications studied, the infectious diseases segment is anticipated to hold the largest share of the viral vaccines market. The demand for vaccines to prevent diseases and reduce morbidity and mortality rates remains a primary driver. The World Health Organization (WHO) estimates that approximately 1.5 million children under the age of five lose their lives each year due to vaccine-preventable diseases, underscoring the urgency for effective viral vaccines. Recent developments, such as the R21/Matrix-M malaria vaccine recommended by the WHO, exemplify the ongoing efforts to combat infectious diseases through vaccination.

Application: Antisense Therapy Segment to Lead
The antisense therapy application segment is expected to hold the largest market share by 2024. The substantial market presence of this segment is attributed to the rising incidence of infectious diseases, advancements in the utilization of viral vectors, and increased healthcare expenditures. Antisense vaccines can induce robust humoral (antibody-mediated) and cellular immune responses, enhancing vaccine efficacy and ensuring widespread adoption.

Geographic Overview: North America to Dominate
From a geographic perspective, North America is projected to lead the viral vaccines market in 2024, driven by several factors, including advanced research infrastructure, the presence of key pharmaceutical companies, and strategic collaborations between research institutes and pharmaceutical firms. The establishment of new facilities in the region by major players and heightened awareness of vaccination amid emerging pandemic risks further bolster the North American market.

Key Players Shaping the Viral Vaccines Market
The viral vaccines market features several key players committed to advancing vaccine development and expanding their market share. Notable companies profiled in the report include:

Pfizer, Inc. (U.S.)
AstraZeneca plc (U.K.)
GlaxoSmithKline plc (U.K.)
Sanofi S.A. (Italy)
CSL Ltd. (Australia)
Mitsubishi Tanabe Pharma Corporation (Japan)
Merck & Co., Inc. (U.S.)
Moderna, Inc. (U.S.)
Johnson & Johnson Services, Inc. (U.S.)
Dynavax Technologies Corporation (U.S.)
Serum Institute of India Pvt. Ltd. (India)
Emergent BioSolutions, Inc. (U.S.)
Bharat Biotech International Limited (BBIL) (India)
Valneva SE (France)
These companies are actively focusing on expanding their product offerings, enhancing manufacturing capabilities, and exploring strategic collaborations to address the evolving landscape of viral vaccines.

Conclusion: A Future of Growth and Innovation
As the viral vaccines market continues to grow, opportunities for innovation and expansion lie ahead. The increasing prevalence of infectious diseases, advancements in vaccine technology, and rising global health awareness will drive demand for effective viral vaccines. The ongoing commitment to research and development, coupled with strategic partnerships among key players, positions the viral vaccines market for sustained growth through 2031 and beyond.

Read Full Report :- https://www.meticulousresearch.com/product/viral-vaccines-market-5920?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=30-09-2024

Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research